{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:11:38Z","timestamp":1792300298953,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s11882-010-0109-z","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T06:32:16Z","timestamp":1272349936000},"page":"229-235","source":"Crossref","is-referenced-by-count":140,"title":["Inflammasome and IL-1\u03b2-Mediated Disorders"],"prefix":"10.1007","volume":"10","author":[{"given":"Hal M.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A.","family":"Wanderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,28]]},"reference":[{"key":"109_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417\u2013426.","journal-title":"Mol Cell"},{"key":"109_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229\u2013265. This is an excellent review of inflammasome function.","DOI":"10.1146\/annurev.immunol.021908.132715"},{"key":"109_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, et al.: Mutation of a new gene encoding a putative pyrin-like protein cause familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301\u2013305.","journal-title":"Nat Genet"},{"key":"109_CR4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"M Mertens","year":"2009","unstructured":"Mertens M, Singh JA: Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009, 36:1118\u20131125.","journal-title":"J Rheumatol"},{"key":"109_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14712590902875518","volume":"9","author":"HM Hoffman","year":"2009","unstructured":"Hoffman HM: Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009, 9:519\u2013531.","journal-title":"Expert Opin Biol Ther"},{"key":"109_CR6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2009.195","volume":"5","author":"S Savic","year":"2009","unstructured":"Savic S, McDermott MF: Inflammation: canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol 2009, 5:529\u2013530.","journal-title":"Nat Rev Rheumatol"},{"key":"109_CR7","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ, et al.: Efficacy and safety of rilonacept (interleukin-1 TRAP) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443\u20132452.","journal-title":"Arthritis Rheum"},{"key":"109_CR8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416\u20132425.","journal-title":"N Engl J Med"},{"key":"109_CR9","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, et al.: The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009, 68:1613\u20131617.","journal-title":"Ann Rheum Dis"},{"key":"109_CR10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.22491","volume":"56","author":"I Aksentijevich","year":"2007","unstructured":"Aksentijevich I, Putnam CD, Remmers EF, et al.: The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273\u20131285.","journal-title":"Arthritis Rheum"},{"key":"109_CR11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","volume":"364","author":"HM Hoffman","year":"2004","unstructured":"Hoffman HM, Rosengren S, Boyle DL, et al.: Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779\u20131785.","journal-title":"Lancet"},{"key":"109_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","volume":"10","author":"A So","year":"2008","unstructured":"So A: Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.","journal-title":"Arthritis Res Ther"},{"key":"109_CR13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","volume":"11","author":"R Zhou","year":"2010","unstructured":"Zhou R, Tardivel A, Thorens B, et al.: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136\u2013140.","journal-title":"Nat Immunol"},{"key":"109_CR14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1517\/14712590903136688","volume":"9","author":"K Maedler","year":"2009","unstructured":"Maedler K, Dharmadhikari G, Schumann DM, St\u00f8rling J: Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 2009, 9:1177\u20131188.","journal-title":"Expert Opin Biol Ther"},{"key":"109_CR15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200808-1274OC","volume":"179","author":"P Gasse","year":"2009","unstructured":"Gasse P, Riteau N, Charron S, et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179:903\u2013913.","journal-title":"Am J Respir Crit Care Med"},{"key":"109_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/1043-4666(93)90024-Y","volume":"5","author":"PF Piguet","year":"1993","unstructured":"Piguet PF, Vesin C, Grau GE, Thompson RC: Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993, 5:57\u201361.","journal-title":"Cytokine"},{"key":"109_CR17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","volume":"320","author":"C Dostert","year":"2008","unstructured":"Dostert C, Petrilli V, Van Bruggen R, et al.: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674\u2013677.","journal-title":"Science"},{"key":"109_CR18","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/sj.jid.5700819","volume":"127","author":"H Watanabe","year":"2007","unstructured":"Watanabe H, Gaide O, Petrilli V, et al.: Activation of the IL-1[beta]-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007, 127:1956\u20131963.","journal-title":"J Invest Dermatol"},{"key":"109_CR19","doi-asserted-by":"crossref","unstructured":"\u2022 Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009, 27:621\u2013668. This is a comprehensive review of autoinflammatory syndromes.","DOI":"10.1146\/annurev.immunol.25.022106.141627"},{"key":"109_CR20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-146-11-200706050-00023","volume":"146","author":"R Belkhir","year":"2007","unstructured":"Belkhir R, Moulonguet-Doleris L, Hachulla E, et al.: Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007, 146:825\u2013826.","journal-title":"Ann Intern Med"},{"key":"109_CR21","first-page":"S378","volume":"46","author":"KM Hull","year":"2003","unstructured":"Hull KM, Aksentijevich I, Singh HK: Efficacy of etanercept for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS) [abstract]. Arthritis Rheum 2003, 46:S378.","journal-title":"Arthritis Rheum"},{"key":"109_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","volume":"117","author":"A Simon","year":"2004","unstructured":"Simon A, Bodar EJ, van der Hilst JC, et al.: Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004, 117:208\u2013210.","journal-title":"Am J Med"},{"key":"109_CR23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/rheumatology\/kem231","volume":"46","author":"E Drewe","year":"2007","unstructured":"Drewe E, Powell RJ, McDermott EM: Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007, 46:1865\u20131866.","journal-title":"Rheumatology"},{"key":"109_CR24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","volume":"29","author":"M Cailliez","year":"2006","unstructured":"Cailliez M, Garaix F, Rousset-Rouvi\u00e8re C, et al.: Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006, 29:763.","journal-title":"J Inherit Metab Dis"},{"key":"109_CR25","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G, et al.: Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009, 161:1199\u20131201.","journal-title":"Br J Dermatol"},{"key":"109_CR26","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ, et al.: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426\u20132437.","journal-title":"N Engl J Med"},{"key":"109_CR27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D, et al.: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302\u2013308.","journal-title":"Ann Rheum Dis"},{"key":"109_CR28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","volume":"15","author":"AMD Zeft","year":"2009","unstructured":"Zeft AMD, Hollister RMD, LaFleur BP, et al.: Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009, 15:161\u2013164.","journal-title":"J Clin Rheumatol"},{"key":"109_CR29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.2005.045245","volume":"65","author":"HD Koning de","year":"2006","unstructured":"de Koning HD, Bodar EJ, Simon A, et al.: Beneficial response to anakinra and thalidomide in Schnitzler\u2019s syndrome. Ann Rheum Dis 2006, 65:54\u2013544.","journal-title":"Ann Rheum Dis"},{"key":"109_CR30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tcb.2007.10.004","volume":"18","author":"B Faustin","year":"2008","unstructured":"Faustin B, Reed JC: Sunburned skin activates inflammasomes. Trends Cell Biol 2008, 18:4\u20138.","journal-title":"Trends Cell Biol"},{"key":"109_CR31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1165\/ajrcmb.41.2.246","volume":"41","author":"AA Wanderer","year":"2009","unstructured":"Wanderer AA: Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1{beta} targeted therapy. Am J Respir Cell Mol Biol 2009, 41:246\u2013247.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"109_CR32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MPH.0b013e3181acd89d","volume":"31","author":"AA Wanderer","year":"2009","unstructured":"Wanderer AA: Rationale for IL-1[beta] targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. J Pediatr Hematol Oncol 2009, 31:537\u2013538.","journal-title":"J Pediatr Hematol Oncol"},{"key":"109_CR33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/jp.2009.114","volume":"29","author":"AA Wanderer","year":"2009","unstructured":"Wanderer AA: Rationale for IL-1[beta]-targeted therapy to minimize hypoxic-ischemic encephalopathy. J Perinatol 2009, 29:785\u2013787.","journal-title":"J Perinatol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11882-010-0109-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T08:29:24Z","timestamp":1551342564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-010-0109-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1007\/s11882-010-0109-z","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,28]]}}}